



FDA Approval Decisions Report August-October 2007

Jeremy Zhou
Senior Analyst
415-782-0454, x158
jzhou@reveredata.com

Daniel Grundig
Analyst
415-782-0454, x176
dgrundig@reveredata.com

Overview

For investors in pharmaceutical and biotech companies, rigorous monitoring of drug pipelines is essential. No milestone is more influential than the FDA approval decision date, frequently called the PDUFA date (from Prescription Drug User Fee Act).

This Revere Report features **companies with expected FDA approval decision dates in the next three months**. To provide further insights into **each drug candidate's likelihood of approval and competitive landscape**, the FDA Approval Decisions Report includes **key data based on Revere's patented classification system and proprietary pipeline database** - specifically, whether each drug candidate:

- utilizes a mechanism of action already approved by the FDA in other drugs
- faces two or fewer alternative drugs with the same mechanism of action for the same indication
- would be the first or second FDA approved drug for the company

Contents

- Recent Approval Results/Updates
- Expected PDUFA Dates in the Next Three Months
- Price and Financial Info

Copyright 2007 by Revere Data, LLC. All rights reserved.

Notes:

1. Some expected PDUFA (Prescription Drug User Fee Act) dates are Revere estimates based on NDA (New Drug Approval) submission dates. Companies are not obligated to disclose NDA submission dates or PDUFA dates, and the FDA may change its approval decision date without prior notice.
2. Drugs developed by private firms or by companies not traded publicly in the U.S. are excluded from this analysis.

Disclaimer:

Revere Data is an independent provider of investment research and information and does not offer broker / dealer, money management, hedge fund management, investment advisory, or investment banking services.

The information contained in this report is based on a limited analysis of qualitative, statistical, and financial data and should not be interpreted as recommendations based on a complete investment evaluation. The information is based on sources that Revere Data believes to be reliable, but no representation, express or implied, is made with respect to the accuracy, completeness, reliability, or timeliness. The information is subject to change without notice, and Revere Data does not accept responsibility to update it.

Revere Data does not accept responsibility or liability for any direct, indirect, special, consequential, or other losses or damages of any kind whatsoever arising out of access to, or use of, this report or any information contained in it.

For more information on Revere's independent research data and investment analytics, please contact us as follows:

Revere Data, LLC | 60 East 42nd St. Suite 716 | New York, NY 110165
866.REVERE9 (866.738.3739) | sales@reveredata.com | www.reveredata.com

Recent Approval Results/Updates

Company (Symbol) / Drug Candidate			
Indications	Primary mode of action (PMOA)	Previous Expected PDUFA Date	Approval results/update
Neurochem Inc. (USA) (NRMX) / Kiacta (Eprodisate)/FormerlyFibrillex			
Amyloid A Amyloidosis (AA Amyloidosis)	Glycosaminoglycan (GAG) Mimetic Agents	<u>07/16/2007</u>	Approvable Letter Received 07/17/2007
DOR BioPharma, Inc. (DORB) / orBec (Oral Beclomethasone Dipropionate)			
Gastrointestinal Graft-Versus-Host Disease (GVHD)	Steroidal Anti-Inflammatory Drugs (SAID)	<u>07/20/2007</u>	Rescheduled to 10/19/2007
Wyeth (WYE) / Pristiq (Desvenlafaxine Succinate)/Formerly DVS-233			
Relief Of Vasomotor Symptoms Associated With Menopause	Selective Norepinephrine Reuptake Inhibitors (SNRI)	<u>07/23/2007</u>	Approvable Letter Received 07/24/2007
VIVUS, Inc. (VVUS) / Evamist (Estradiol Metered-Dose Transdermal System)			
Relief Of Symptoms Associated With Menopause	Estrogens	<u>07/27/2007</u>	Approved 07/30/2007
sanofi-aventis (ADR) (SNY) / Zimulti (Rimonabant)/Formerly Acomplia			
Treatment Of Obesity	Cannabinoid Receptor Antagonists	<u>07/27/2007</u>	Canceled
K-V Pharmaceutical Company (KV/A) / Evamist (Estradiol Metered-Dose Transdermal System)			
Relief Of Symptoms Associated With Menopause	Estrogens	<u>07/27/2007</u>	Approved 07/30/2007
Gilead Sciences, Inc. (GILD) / Tamiflu (Oseltamivir)			
Prophylaxis And Treatment Of Influenza A And Influenza B In Children Ages One And Older In Capsule Formulation	Neuraminidase Inhibitors	01/09/2008	Approved 07/02/2007
Roche Holding Ltd. (ADR) (RHHBY) / Tamiflu (Oseltamivir)			
Prophylaxis And Treatment Of Influenza A And Influenza B In Children Ages One And Older In Capsule Formulation	Neuraminidase Inhibitors	01/09/2008	Approved 07/02/2007

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases.






Expected PDUFA Dates in the Next Three Months

August Drug Candidates

Companies

Endo Pharmaceuticals (ENDP)
 GlaxoSmithKline plc (ADR) (GSK)
 IDM Pharma Inc. (IDMI)
 Indevus Pharmaceuticals (IDEV)
 POZEN Inc. (POZN)
 Sciele Pharma Inc. (SCRX)
 Solvay S.A. (ADR) (SVYSY)
 Tercica, Inc. (TRCA)
 Vernalis plc (ADR) (VNLSY)
 Wyeth (WYE)

Sectors

I Biopharmaceuticals
 Endocrinology/Metabolism
 Hematology
 Neurology
 Oncology
 Urology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
GlaxoSmithKline plc (ADR) (GSK) / Trexima (Naproxen/Sumatriptan)						
	First-Line Therapy For Migraine Headaches	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	<u>08/01/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
POZEN Inc. (POZN) / Trexima (Naproxen/Sumatriptan)						
	First-Line Therapy For Acute Migraine Attacks	Non-Steroidal Anti-Inflammatory Drugs (NSAID)/Selective Serotonin Receptor Agonists	<u>08/01/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Wyeth (WYE) / Bifeprunox						
	Schizophrenia	Serotonin/Dopamine Receptor Partial Agonists	08/10/2007	Yes	Yes Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet) / (BMY)	No
Solvay S.A. (ADR) (SVYSY) / Solvay Pharmaceuticals Bifeprunox						
	Schizophrenia	Serotonin/Dopamine Receptor Partial Agonists	08/10/2007	Yes	Yes Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet) / (BMY)	No
Indevus Pharmaceuticals (IDEV) / SANCTURA XR (Trospium Chloride)						
	Overactive Bladder With Symptoms Of Urinary Incontinence, Urgency, And Frequency	Muscarinic Receptor Antagonists	<u>08/13/2007</u>	Yes	No Multiple Drugs	No
Vernalis plc (ADR) (VNLSY) / Frova (Frovatriptan Succinate)						
	Menstrually-Associated Migraine	Selective Serotonin Receptor Agonists (Triptans)	<u>08/17/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Endo Pharmaceuticals (ENDP) / Frova (Frovatriptan Succinate)						
	Menstrually Related Migraine	Selective Serotonin Receptor Agonists (Triptans)	<u>08/17/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	No
Sciele Pharma Inc. (SCRX) / LCP-FenoChol (Fenofibrate)						
	Adjunctive Therapy To Diet For Treatment Of Hypertriglyceridemia And Hypercholesterolemia	Plasma Triglyceride Reducing Agents (Fibrate Compounds)	08/20/2007	Yes	No Multiple Drugs	No

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
IDM Pharma Inc. (IDMI) / MTP-PE (Mifamurtide)/Formerly Junovan						
	Newly Diagnosed Resectable High Grade Osteosarcoma (Bone Cancer) In Combination With Chemotherapies	Macrophage Activators	<u>08/24/2007</u>	No	Yes Only Candidate with This PMOA for This Indication	Yes
Tercica, Inc. (TRCA) / Somatuline Autogel						
	Acromegaly	Somatostatin Analogs	<u>08/30/2007</u>	Yes	Yes Sandostatin/Sandostatin LAR (Octreotide Acetate) / (NVS)	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

September Drug Candidates

Companies

Anesiva, Inc. (ANSV)
Eli Lilly & Co. (LLY)
Novartis AG (ADR) (NVS)
Omrix Biopharmaceuticals, Inc. (OMRI)

Sectors

- I Biopharmaceuticals
 - Musculoskeletal System
 - Oncology
 - Pain Management
 - Surgery

Notes:

1. Some drug candidates are filed jointly by two companies.
2. Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Eli Lilly & Co. (LLY) / Evista (Raloxifene Hydrochloride)						
	Prevention Of Invasive Breast Cancer In Postmenopausal Women With Osteoporosis And At High Risk For Breast Cancer	Selective Estrogen Receptor Modulators (SERM)	September 2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Novartis AG (ADR) (NVS) / Prexige (Lumiracoxib)						
	Osteoarthritis (OA)	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)	September 2007	Yes	No Multiple Drugs	No
Omrix Biopharmaceuticals, Inc. (OMRI) / Thrombin						
	Human Plasma-Derived Thrombin For Hemostasis (Bleeding Control) During Surgical Procedures	Coagulating Agents (Coagulants)	09/06/2007	Yes	Yes rThrombin / (ZGEN) Thrombin JMI / (KG)	No
Anesiva, Inc. (ANSV) / Zingo (PowderJect Dermal Lidocaine)/Formely 3268						
	Pain Reduction Associated With Venipuncture Procedures In Children	Sodium Channel Blocking Agents	<u>09/24/2007</u>	Yes	Yes Synera Patch (Lidocaine/Tetracaine) / (ENDP)	Yes











Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

October Drug Candidates

Companies

Adams Respiratory Therapeutics, Inc. (ARXT)
 Biogen Idec Inc. (BIIB)
 Biovail Corporation (USA) (BVF)
Bristol Myers Squibb Co. (BMY) [3]
 Cardiome Pharma Corp.(USA) (CRME)
 DOR BioPharma, Inc. (DORB)
 DepoMed, Inc. (DEPO)
 Elan Corporation, plc (ADR) (ELN)
 Genentech, Inc. (DNA)
 Genzyme Corporation (GENZ)
 GlaxoSmithKline plc (ADR) (GSK)
 ImClone Systems Incorporated (IMCL)
 Indevus Pharmaceuticals (IDEV)
 Johnson & Johnson (JNJ)
 King Pharmaceuticals, Inc. (KG)
Merck & Co., Inc. (MRK) [3]
 Novartis AG (ADR) (NVS)
 Roche Holding Ltd. (ADR) (RHHBY)
 Theravance, Inc. (THRX)
 ZymoGenetics, Inc. (ZGEN)
 sanofi-aventis (ADR) (SNY)

Sectors

- I** Biopharmaceuticals
-  Cardiovascular System
 -  Endocrinology/Metabolism
 -  Immunology
 -  Infectious Diseases
 -  Neurology
 -  Oncology
 -  Respiratory System
 -  Surgery
 -  Transplantation
 -  Urology

Notes:

- Some drug candidates are filed jointly by two companies.
- Companies with multiple drug candidates in the same month are shown in **bold type** with the number of drug candidates in brackets [].

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Biovail Corporation (USA) (BVF) / Glumetza (Metformin GR)	Once Daily Formulation For The Treatment Of Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides	10/02/2007	Yes	Yes Glucophage XR (Metformin Hydrochloride Extended Release) / (BMY) Fortamet (Metformin Extended Release) / (SCRX)	No
DepoMed, Inc. (DEPO) / Glumetza (Metformin GR)	Once Daily Formulation For The Treatment Of Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides	10/02/2007	Yes	Yes Glucophage XR (Metformin Hydrochloride Extended Release) / (BMY) Fortamet (Metformin Extended Release) / (SCRX)	No
King Pharmaceuticals, Inc. (KG) / Glumetza (Metformin GR)	Once Daily Formulation For The Treatment Of Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Biguanides	10/02/2007	Yes	Yes Glucophage XR (Metformin Hydrochloride Extended Release) / (BMY) Fortamet (Metformin Extended Release) / (SCRX)	No
Bristol Myers Squibb Co. (BMY) / Abilify (Aripiprazole)/Abilify Discmelt (Aripiprazole Orally Disintegrating Tablet)	Treatment Of Schizophrenia In Pediatric Patients 13-17 Years Old	Serotonin/Dopamine Receptor Partial Agonists	10/05/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Bristol Myers Squibb Co. (BMY) / Erbitux (Cetuximab)	Third-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer)	Monoclonal Antibodies	10/08/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
ImClone Systems Incorporated (IMCL) / Erbitux (Cetuximab)						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Theravance, Inc. (THRX) / Telavancin						
	Third-Line Treatment Of Metastatic Colorectal Cancer (Colon Cancer)	Monoclonal Antibodies	10/08/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
GlaxoSmithKline plc (ADR) (GSK) / Hycamtin Oral (Topotecan Hydrochloride)						
	Relapsed Small Cell Lung Cancer (SCLC)	Topoisomerase I Inhibitors	10/12/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Johnson & Johnson (JNJ) / Doripenem						
	Complicated Intra-Abdominal Infection, Complicated Urinary Tract Infection	Carbapenems	10/15/2007	Yes	No Multiple Drugs	No
Biogen Idec Inc. (BIIB) / Tysabri (Natalizumab)						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	10/15/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Elan Corporation, plc (ADR) (ELN) / Tysabri (Natalizumab)						
	Moderately To Severely Active Crohn's Disease	Alpha 4 Integrin Inhibitors	10/15/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Merck & Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)						
	Adjunct To Diet And Exercise, And As Add-On Therapy To A Sulfonylurea In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes, Add-On Therapy To The Combination Of A Sulfonylurea Plus Metformin In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/15/2007	Yes	Yes Saxagliptin / (BMY) Galvus (Vildagliptin) / (NVS)	No
Merck & Co., Inc. (MRK) / Januvia (Sitagliptin Phosphate)						
	Adjunct To Diet And Exercise, And In Combination With Metformin To Improve Glycemic Control In Non-Insulin Dependent Diabetes Mellitus (NIDDM)/Type 2 Diabetes	Dipeptidyl Peptidase (DPP) Inhibitors	10/15/2007	Yes	Yes Saxagliptin / (BMY) Galvus (Vildagliptin) / (NVS)	No
Novartis AG (ADR) (NVS) / Tasigna (Nilotinib)						
	Chronic Myeloid Leukemia (CML)/Acute Lymphoblastic Leukemia (ALL) Resistant To Gleevec	Tyrosine Kinase Inhibitors	<u>10/16/2007</u>	Yes	Yes Sprycel (Dasatinib) / (BMY)	No
Merck & Co., Inc. (MRK) / Isentress (Raltegravir)/Formely MK-0518						
	Human Immunodeficiency Virus (HIV) Infection	Integrase Inhibitors, Integrase inhibitors	10/17/2007	No	Yes Only Candidate with This PMOA for This Indication	No
ZymoGenetics, Inc. (ZGEN) / rThrombin						
	Reduce Bleeding During Surgery/Critical Care (Hemostat)	Coagulating Agents (Coagulants)	<u>10/18/2007</u>	Yes	Yes Thrombin / (OMRI) Thrombin JMI / (KG)	Yes
Indevus Pharmaceuticals (IDEV) / Valera Valstar (Valrubicin)						

Company (Symbol) / Drug Candidate	Indications	Primary mode of action (PMOA)	Expected PDUFA Date	Proven PMOA?	Two or Fewer Alternatives?	1 st /2 nd Drug?
Intravesical Therapy Of BCG-Refractory Urinary Bladder Cancer In Patients For Whom Cystectomy Would Not Be Appropriate						
		Topoisomerase II Inhibitors	10/19/2007	Yes	Yes Adriamycin (Doxorubicin Hydrochloride) / (PFE)	No
Bristol Myers Squibb Co. (BMY) / Ixabepilone (Epothilone B)						
	Monotherapy To Treat Patients With Metastatic Or Locally Advanced Breast Cancer After Failure Of Chemotherapies	Antimicrotubule Agents	10/19/2007	Yes	No Multiple Drugs	No
DOR BioPharma, Inc. (DORB) / orBec (Oral Beclomethasone Dipropionate)						
	Gastrointestinal Graft-Versus-Host Disease (GVHD)	Steroidal Anti-Inflammatory Drugs (SAID)	<u>10/19/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes
Genentech, Inc. (DNA) / Herceptin (Trastuzumab)						
	In Combination With Taxotere As First-Line Treatment Of HER-2 Positive Metastatic Breast Cancer	Monoclonal Antibodies	10/19/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Roche Holding Ltd. (ADR) (RHHBY) / Herceptin (Trastuzumab)						
	In Combination With Taxotere As First-Line Treatment Of HER-2 Positive Metastatic Breast Cancer	Monoclonal Antibodies	10/19/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Cardiome Pharma Corp.(USA) (CRME) / RSD1235 I.V. (Vernakalant)						
	Acute Conversion Of Atrial Fibrillation	Sodium Channel Blocking Agents/Potassium Channel Blocking Agents	<u>10/19/2007</u>	Yes	Yes Lanoxin (Digoxin) / (GSK)	Yes
Genzyme Corporation (GENZ) / Renvela (Sevelamer Carbonate)						
	Reduction Of Serum Phosphorus In Patients With Chronic Kidney Disease On Dialysis	Phosphate Binding Agents	10/20/2007	No	Yes Fosrenol (Lanthanum Carbonate) / (SHPGY) PhosLo (Calcium Acetate) / (FMS)	No
sanofi-aventis (ADR) (SNY) / Taxotere (Docetaxel)						
	Induction Therapy Of Locally Advanced Head And Neck Cancer Prior To Chemoradiotherapy And Surgery	Antimicrotubule Agents	10/26/2007	Yes	Yes Only Candidate with This PMOA for This Indication	No
Adams Respiratory Therapeutics, Inc. (ARXT) / Guaifenesin Combination Extended-Release Product						
	Cough Relief	Expectorants	<u>10/26/2007</u>	Yes	Yes Only Candidate with This PMOA for This Indication	Yes

Expected PDUFA Dates are Revere estimates based on NDA (New Drug Approval) submission dates. Underlined dates indicate that Revere has confirmed directly with the company or indirectly through company filings and press releases. **Two or Fewer Alternatives** -- If Approved, Drug Will Likely Face Two or Fewer Alternatives in Same Drug Class for Same Indication? **1st/2nd Drug** -- 1st or 2nd FDA Approved Drug of the Company?

Price and Financial Info

August 2007

Data as of 08/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Endo Pharmaceuticals	ENDP	34.04	4,553.647	1,448,811	5.41	1.41	730.9	6.44%	1.03%
GlaxoSmithKline plc (ADR)	GSK	51.10	145,516.282	2,539,472	11.54	57.41	5,976.5	-6.72%	-12.12%
IDM Pharma Inc.	IDMI	2.18	39.081	286,180	3.91	3.18	18.5	-11.53%	-16.94%
Indevus Pharmaceuticals	IDEV	7.09	524.514	874,110	n/a	0	59.0	32.03%	26.62%
POZEN Inc.	POZN	17.72	522.394	850,936	22.13	0	58.2	136.54%	131.13%
Sciele Pharma Inc.	SCRX	23.24	819.489	599,085	7.80	37.1	175.3	16.61%	11.20%
Solvay S.A. (ADR)	SVYSY	149.00	12,620.468	n/a	3.65	47.85	641.8	26.00%	20.60%
Tercica, Inc.	TRCA	4.80	240.776	147,932	3.04	31.99	110.7	-4.00%	-9.41%
Vernalis plc (ADR)	VNLSY	2.25	352.463	n/a	n/a	76.38	75.0	-16.36%	-21.76%
Wyeth	WYE	49.05	65,980.092	9,251,184	n/a	n/a	n/a	1.09%	-4.31%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

September 2007

Data as of 08/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Anesiva, Inc.	ANSV	6.38	175.681	24,467	2.23	0.24	71.7	-11.88%	-17.29%
Eli Lilly & Co.	LLY	54.24	61,510.496	5,161,732	n/a	n/a	n/a	-3.64%	-9.05%
Novartis AG (ADR)	NVS	53.68	125,337.428	2,858,972	5.54	17.06	7,548.0	-4.65%	-10.06%
Omxix Biopharmaceuticals, Inc.	OMRI	28.61	482.051	313,030	4.49	0.94	83.7	131.10%	125.69%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,

October 2007

Data as of 08/01/2007

Name	Ticker	Last Price	Market Cap.	30d Avg. Volume	Price To Tang. Book Value	Total Debt to Equity %	Cash & Equiv.+ ST Inv.	1 Year Return %	Rel. Perf. vs. ^BPHRM
Adams Respiratory Therapeutics, Inc.	ARXT	37.51	1,336.123	617,944	8.95	0	70.7	-14.01%	-19.41%
Biogen Idec Inc.	BIIB	56.51	16,270.681	5,174,412	18.62	1.36	1,802.7	37.73%	32.32%
Biovail Corporation (USA)	BVF	18.97	3,045.795	1,282,860	5.45	30.69	870.2	-9.45%	-14.86%
Bristol Myers Squibb Co.	BMJ	28.43	55,952.089	11,267,102	n/a	n/a	n/a	19.45%	14.05%
Cardiome Pharma Corp.(USA)	CRME	8.64	547.077	492,439	11.93	2.44	51.3	-28.71%	-34.12%
DepoMed, Inc.	DEPO	2.21	104.909	2,020,964	n/a	0	25.8	-48.36%	-53.77%
DOR BioPharma, Inc.	DORB	0.28	25.953	756,985	6.64	0	5.2	12.00%	6.59%
Elan Corporation, plc (ADR)	ELN	18.59	8,691.441	5,219,884	n/a	0	836.9	23.94%	18.53%
Genentech, Inc.	DNA	74.63	78,598.070	3,972,592	n/a	n/a	n/a	-7.33%	-12.73%
Genzyme Corporation	GENZ	62.93	16,616.509	4,140,488	4.85	0	1,500.1	-7.46%	-12.86%
GlaxoSmithKline plc (ADR)	GSK	51.10	145,516.282	2,539,472	11.54	57.41	5,976.5	-6.72%	-12.12%
ImClone Systems Incorporated	IMCL	33.10	2,839.921	1,271,064	3.53	74.65	1,070.0	1.94%	-3.47%
Indevus Pharmaceuticals	IDEV	7.09	524.514	874,110	n/a	0	59.0	32.03%	26.62%
Johnson & Johnson	JNJ	61.00	176,690.037	13,751,628	n/a	n/a	n/a	-2.68%	-8.09%
King Pharmaceuticals, Inc.	KG	16.95	4,130.095	3,398,968	3.52	16.6	818.4	-1.97%	-7.37%
Merck & Co., Inc.	MRK	50.81	110,119.141	13,846,552	n/a	n/a	n/a	24.47%	19.07%

Novartis AG (ADR)	NVS	53.68	125,337.428	2,858,972	5.54	17.06	7,548.0	-4.65%	-10.06%
Roche Holding Ltd. (ADR)	RHHBY	89.10	153,708.642	n/a	6.14	17.99	19,373.7	-0.06%	-5.46%
sanofi-aventis (ADR)	SNY	40.56	110,277.329	2,533,459	n/a	n/a	n/a	-14.16%	-19.57%
Theravance, Inc.	THRX	25.65	1,546.076	467,752	n/a	0	150.7	8.73%	3.33%
ZymoGenetics, Inc.	ZGEN	11.26	766.899	636,121	3.63	31.79	224.0	-37.51%	-42.92%

Definitions: Market Cap. - Market Capitalization, Price To Tang. Book Value - Price to Tangible Book Value, Cash & Equiv.+ ST Inv. - Cash and Equivalents + Short-Term Investments, Rel. Perf. vs. ^BPHRM - Relative Performance vs. Revere Biopharm Index,